[4-[2-[2-(Dimethylamino)-2-oxoethoxy]-2-oxoethyl]phenyl] 4-(hydrazinylmethylideneamino)benzoate;methanesulfonic acid

• 分子结构分类: 有机化合物 - 苯丙烷和聚酮 - 缩酚酸和缩酚酸环醚类
• 英文名称: [4-[2-[2-(Dimethylamino)-2-oxoethoxy]-2-oxoethyl]phenyl] 4-(hydrazinylmethylideneamino)benzoate;methanesulfonic acid
• 英文别名: [4-[2-[2-(dimethylamino)-2-oxoethoxy]-2-oxoethyl]phenyl] 4-(hydrazinylmethylideneamino)benzoate;methanesulfonic acid
• 化学式: C21H26N4O8S
• 分子量: 494.5
• InChiKey: NKBSKUKGZJAMAE-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.71
• 重原子数：
  34
• 可旋转键数：
  10
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.24
• 拓扑面积：
  186
• 氢给体数：
  3
• 氢受体数：
  10

文献信息

• Serine protease inhibitor for treating coronavirus infection
  申请人：RedHill Biopharma Ltd.

  公开号：US11045453B1

  公开（公告）日：2021-06-29

  The disclosure is directed to WX-671, as (L)- or (D)-enantiomers, and as E- or (Z)-isomers or (E/Z)-mixtures, and as free bases or as salts thereof, in preparing medicines for treating coronavirus infection or preventing diseases caused by coronavirus infection, and a medicine for preventing coronavirus infection or preventing diseases caused by coronavirus infection.

  本公开涉及 WX-671，作为（L）-或（D）-对映体，以及作为 E-或（Z）-异构体或（E/Z）-混合物，以及作为游离碱或其盐，用于制备治疗冠状病毒感染或预防冠状病毒感染引起的疾病的药物，以及用于预防冠状病毒感染或预防冠状病毒感染引起的疾病的药物。
• COMPOSITIONS COMPRISING A SINGLE VARIABLE DOMAIN AND CAMOSTAT MESYLATE (CM)
  申请人：Glaxo Group Limited

  公开号：EP2887960A2

  公开（公告）日：2015-07-01
• COMPOSITIONS COMPRISING AN ANTIBODY AND CAMOSTAT MESYLATE (CM)
  申请人：Glaxo Group Limited

  公开号：EP2888276A2

  公开（公告）日：2015-07-01
• COMPOSITION COMPRISING A SINGLE VARIABLE DOMAIN AND CAMOSTAT MESYLATE (CM)
  申请人：Glaxo Group Limited

  公开号：US20150306058A1

  公开（公告）日：2015-10-29

  The present disclosure provides a means of stabilising a single variable domain, in particular in protease-rich environments such as the stomach and intestine. A composition, in particular a pharmaceutical composition, comprising a single variable domain and camostat mesylate is provided, together with uses of said composition as a medicament and in methods of treatment. Compositions of the disclosure are particularly useful in the topical treatment of gastrointestinal conditions, such as Crohn's Disease or ulcerative colitis, or for direct activity in the gut mucosal immune system.
• SERINE PROTEASE INHIBITOR FOR TREATING CORONAVIRUS INFECTION
  申请人：RedHill Biopharma Ltd.

  公开号：US20210299108A1

  公开（公告）日：2021-09-30

  The disclosure is directed to WX-671, as (L)- or (D)-enantiomers, and as E- or (Z)-isomers or (E/Z)-mixtures, and as free bases or as salts thereof, in preparing medicines for treating coronavirus infection or preventing diseases caused by coronavirus infection, and a medicine for preventing coronavirus infection or preventing diseases caused by coronavirus infection.